The Federal Assault on Transgender Youth: Deconstructing the War on Gender-Affirming Healthcare

Newcastle, WA – On August 11, 2026, the Centers for Medicare & Medicaid Services (CMS) finalized a rule titled Prohibition on Federal Medicaid and Children's Health Insurance Program Funding for Sex-Rejecting Procedures Furnished to Children.¹ Published in the Federal Register on August 13 and effective October 13, 2026, it cuts off federal Medicaid reimbursement for puberty blockers, cross-sex hormone therapy, and related surgeries for transgender youth under 18 on Medicaid and under 19 on CHIP, with only a six-month transition window for enrollees already receiving non-GnRH hormone therapy.¹

It is not a routine fiscal adjustment. It is the third act in a sustained campaign by this administration to dismantle healthcare access for transgender minors through federal administrative and fiscal power rather than legislation.

A Campaign in Stages

The campaign has moved in stages. First, on January 28, 2025, the administration issued Executive Order 14187,² threatening to cut federal funding to medical institutions that provide gender-affirming care; Washington and other states sued the following month, challenging it as unconstitutional. That case was argued before the Ninth Circuit Court of Appeals³ in March 2026 and remains pending.

Then, on December 18, 2025, HHS Secretary Robert F. Kennedy Jr. issued a formal declaration⁴ asserting that gender-affirming care for minors does not meet "professionally recognized standards of health care," opening providers to enforcement action for billing the federal government for it. A coalition sued to block it⁵ in the U.S. District Court for the District of Oregon days later. On April 18, 2026, a federal judge vacated the declaration entirely and permanently enjoined HHS from enforcing it or anything materially similar.⁶

The August 2026 CMS rule is the culmination. Rather than threatening providers directly, it changes what federal healthcare dollars will pay for at all.

Each step did real damage before any court weighed in. That is the point.

Critique of the Federal Mandate

CMS grounds the rule in sections 1902(a)(19) and 1902(a)(30)(A) of the Social Security Act, arguing that gender-affirming care for minors fails to meet Medicaid's "quality of care" and "best interest of beneficiaries" standards. The rule carves out exceptions for medically verifiable disorders of sexual development, precocious puberty unrelated to gender dysphoria, complications arising from prior treatment, and mental health services or psychotherapy for gender dysphoria itself.

What it does not exempt is the same medications and procedures used to treat gender dysphoria in transgender youth. That distinction, the same drug producing a different funding outcome depending on why a patient needs it, is the crux of the discrimination claim being made against the rule, and it is a precise one worth stating precisely rather than overstating.

The Human Toll

Roughly 16,900 young people ages 13 to 17 in Washington identify as transgender, about 3.4 percent of that age group, per the Williams Institute at UCLA.¹² Nearly 850,000 children in Washington receive coverage through Apple Health, the state's Medicaid/CHIP program.¹³ Nationally, an estimated 130,000 transgender young people rely on Medicaid or CHIP in states that have not already restricted this care, according to KFF.¹⁴

Access was already limited before this rule. Public Health, Seattle & King County's 2021 Pride Survey Report found that 57% of transgender and gender-diverse respondents had an unmet need for gender-affirming care.¹⁵ This federal action does not create that gap; it widens one that already existed.

The mental health stakes are well documented. The Trevor Project's 2025 national survey¹⁶ found that 36% of LGBTQ+ young people seriously considered suicide in the past year, rising to 43% among transgender boys and men and 41% among transgender girls and women. The same survey found that transgender and nonbinary youth who wanted gender-affirming hormones but could not access them attempted suicide at nearly twice the rate of those who could get them, 15% versus 8%, and that 87% of transgender and nonbinary youth currently on hormones worried about losing access. That correlation between hormone access and reduced suicidality is echoed in peer-reviewed research, including Turban et al.'s 2022 study,¹⁷ linking adolescent access to gender-affirming hormones to significantly lower rates of suicidal ideation in adulthood.

On the CMS rule specifically, over 90% of the roughly 11,000 publicly posted comments opposed it, out of nearly 35,000 submitted.¹¹⁴ CMS's own fiscal analysis put combined federal and state Medicaid/CHIP spending on this care at about $31 million in 2023, against a projected $235 million reduction in total Medicaid and CHIP spending from 2027 through 2036, $138 million of it federal¹, a small line item against a Medicaid and CHIP program that cost the federal government $691 billion in 2025 alone, according to the Committee for a Responsible Federal Budget's analysis of CBO's February 2026 baseline.¹⁸ The financial rationale for the rule is thin relative to its human cost.

Case Study in Institutional Collapse: Mary Bridge Children's Hospital

MultiCare Mary Bridge Children's Hospital in Tacoma closed its pediatric gender health clinic in late January 2026,¹⁹ not because of any clinical failure, but preemptively, in response to the threat of losing federal funding entirely. At the time of closure, the clinic was serving roughly 320 patients, about 180 of them under 18, with a waitlist of around 150 additional families reported months earlier.

MultiCare CEO Bill Robertson pointed to both the Kennedy declaration and the then-proposed CMS rule as the reason,²⁰ warning that continuing to provide this care risked the loss of Medicare and Medicaid funding across the entire MultiCare system, on which roughly 62% of Mary Bridge's patients and about 75% of MultiCare's broader patient base depend. MultiCare's own statement called it "an incredibly painful decision, and one that we wish we did not have to make."

Legal observers at the time noted the closure came before the CMS rule was even final, and while gender-affirming care remained fully legal under Washington law. That is the mechanism worth naming: the federal government does not need to win in court, or even finish a rulemaking, to shut a clinic down. The threat alone can do it, because hospital systems facing total Medicare and Medicaid defunding will rationally choose to preserve the rest of their operations over one clinic, whatever state law says.

The Washington Resistance

Washington's defense against this campaign has run on three legal tracks, each responding to a different piece of the federal action, plus one statutory shield already in state law. One of those tracks, the Oregon case, has already produced a win.

HB 1469

Signed in April 2023, HB 1469²¹ is Washington's shield law protecting reproductive and gender-affirming care providers, patients, and the people who help them from out-of-state legal action and investigation.

The Ninth Circuit Case

Originally filed February 2025 and argued March 2026,³ this case challenges the administration's executive orders threatening to cut federal research and institutional funding over gender-affirming care. Washington's argument there is that the orders violate the Fifth Amendment's equal protection guarantee by singling out transgender people for mistreatment, and that the president cannot unilaterally override Congress's own spending decisions.

The Oregon Case

Oregon v. Kennedy,⁴ filed December 2025⁵ in the District of Oregon, challenged the HHS declaration itself, arguing it was issued without the notice-and-comment process federal law requires and improperly intruded on states' traditional authority over the practice of medicine. On April 18, 2026, the court agreed: it vacated the declaration and permanently enjoined HHS from enforcing it, ruling that the agency lacks authority to unilaterally override professionally recognized standards of care.⁶

The Massachusetts Case

Filed September 2, 2026²² in the District of Massachusetts, this is the most recent and most direct challenge, targeting the finalized CMS Medicaid/CHIP rule itself. The suit argues the rule exceeds CMS's statutory authority under the Administrative Procedure Act and violates the Spending Clause, and invokes the Federal Advisory Committee Act and Section 1554 of the Affordable Care Act among its supporting theories.¹¹

Central to it is the argument that the rule conflicts with the Medicaid Drug Rebate Program: under Section 1927 of the Social Security Act, states must cover FDA-approved drugs for medically accepted indications, and because standard pharmaceutical compendia already list gender dysphoria as such an indication, CMS is attempting to override its own program's statutory baseline by administrative fiat.

Attorney General Nick Brown called the rule an example of the administration "once again claiming powers it does not have" to foreclose healthcare options "that should be left to Washington youth, their doctors, and their families."²²

Washington has also had to absorb related federal funding losses on a separate track: after Congress cut Medicaid reimbursements to Planned Parenthood in 2025, Governor Bob Ferguson committed roughly $11 million in state funds to backfill the gap.²³ It is not caused by the CMS gender-affirming care rule, but it is part of the same broader pattern of the state stepping in as the federal government withdraws from healthcare it previously funded.

Conclusion

Three lawsuits, a state shield law, and a governor's backfill commitment are what it currently takes to hold this ground. One of those lawsuits has already won: Oregon's court vacated the Kennedy declaration in April 2026. But that ruling came three months after Mary Bridge had already closed its doors preemptively. The strategy on the federal side does not require winning in court, or even keeping a policy standing. It requires making the cost of continuing to provide care high enough, for long enough, that institutions comply in advance of any ruling at all.

What that means for advocates and legislators in Washington: the state's Medicaid financing exposure from federal healthcare rollbacks generally, not just this rule, deserves close tracking as the remaining cases proceed, since providers appear willing to preempt final rulings rather than risk their broader federal funding. HB 1469 and the still-pending Ninth Circuit and Massachusetts litigation are the legal backstops, but they only protect a right that providers can still be pressured into not exercising, and a win in Oregon didn't undo the closure it came too late to prevent. Medical necessity should be determined by clinicians and patients. Right now, in Washington, it is also being determined by which hospital administrators are willing to bet on litigation they have not yet seen resolved.

Sources